NEUROLOGIE PRO PRAXI / Neurol. praxi. 2025;26(5):373-384 / www.neurologiepropraxi.cz 384 HLAVNÍ TÉMA Aktuálne trendy v diagnostike a liečbe CIDP J Peripher Nerv Syst. 2020;25(2):152-161. doi:10.1111/jns.12378. 41. Loewenbruck KF, Dittrich M, Bohm J, et al. Practically applicable nerve ultrasound models for the diagnosis of axonal and demyelinating hereditary motor and sensory neuropathies (HMSN). J Neurol. 2018;265(1):165-177. doi:10.1007/ s00415-017-8687-5. 42. Lozeron P, Lacour MC, Vandendries C, et al. Contribution of plexus MRI in the diagnosis of atypical chronic inflammatory demyelinating polyneuropathies. J Neurol Sci. 2016;360:170175. doi:10.1016/j.jns.2015.11.048. 43. Lucke IM, Peric S, van Lieverloo GGA, et al. Elevated leukocyte count in cerebrospinal fluid of patients with chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst. 2018;23(1):49-54. doi:10.1111/jns.12250. 44. Lucke IM, Wieske L, van der Kooi AJ, van Schaik IN, Eftimov F, Verhamme C. Diagnosis and treatment response in the asymmetric variant of chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst. 2019;24(2):174-179. doi:10.1111/jns.12325. 45. Łukawska M, Potulska-Chromik A, Lipowska M, et al. Pediatric CIDP: Diagnosis and Management. A Single-Center Experience. Front Neurol. 2021 Jul 2;12:667378. doi: 10.3389/ fneur.2021.667378. 46. Lunn MP, Ellis L, Hadden RD, et al. A proposed dosing algorithm for the individualized dosing of human immunoglobulin in chronic inflammatory neuropathies. J Peripher Nerv Syst. 2016;21:33-37. 47. Maisonobe T, Chassande B, Vérin M, Jouni M, Léger JM, Bouche P. Chronic dysimmune demyelinating polyneuropathy: a clinical and electrophysiological study of 93 patients. J Neurol Neurosurg Psychiatr. 1996;61(1):36-42. doi:10.1136/jnnp.61.1.36. 48. Mansour M, Ouerdiene A, Bedoui I, Kacem A, Zaouali J, Mrissa R. Acute-onset chronic inflammatory demyelinating polyneuropathy with cranial nerves and respiratory tract involvement: A case report. Clin Case Rep. 2020 Jul 24;8(11):21992203. doi: 10.1002/ccr3.3087. 49. Markvardsen LH, Debost JC, Harbo T, et al. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2013;20:836-842. 50. Matsuoka N, Kohriyama T, Ochi K, et al. Detection of cervical nerve root hypertrophy by ultrasonography in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Sci. 2004;219(1-2):15-21. doi:10.1016/j.jns.2003.11.011. 51. McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy: a clinical and electrophysiological study of 92 cases. Brain. 1987;110(6):16171630. doi:10.1093/brain/110.6.1617. 52. Mehndiratta MM, Hughes RA, Pritchard J. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2015;2015(8):CD003906. doi:10.1002/14651858.CD003906.pub4. 53. Mondelli M, Aretini A, Arrigucci U, et al. Clinical findings and electrodiagnostic testing in 108 consecutive cases of lumbosacral radiculopathy due to herniated disc. Neurophysiol Clin. 2013;43(4):205-215. doi: 10.1016/j.neucli.2013.05.004. 54. Mortzell Henriksson M, Newman E, Witt V, et al. Adverse events in apheresis: an update of the WAA registry data. Transfus Apher Sci. 2016;54(1):2-15. doi:10.1016/j.transci.2016.01.003 55. Nobile-Orazio E, Cocito D, Jann S, et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol. 2012;11:493-502. 56. Nobile-Orazio E, Cocito D, Jann S, et al. Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP. J Neurol Neurosurg Psychiatry. 2015;86:729-734. 57. Nobile-Orazio E, Pujol S, Kasiborski F, et al. An international multi center efficacy and safety study of IqYmune in initial and mainte nance treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy: PRISM study. J Peripher Nerv Syst. 2020;25:356-365. 58. Oaklander AL, Lunn MPT, Hughes RA, et al. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Cochrane Database Syst Rev. 2017;2017(1). doi:10.1002/14651858. 59. Oh SJ, Claussen GC, Kim DS. Motor and sensory demyelinating mononeuropathy multiplex (multifocal motor and sensory demyelinating neuropathy): a separate entity or a variant of chronic inflammatory demyelinating polyneuropathy? J Peripher Nerv Syst. 1997;2(4):362-369. 60. Oudeman J, Eftimov F, Strijkers GJ, et al. Diagnostic accuracy of MRI and ultrasound in chronic immune-mediated neuropathies. Neurology. 2020;94(1):e62-e74. doi:10.1212/ WNL.0000000000008697. 61. Padua L, Caliandro P, Aprile I, et al. Occurrence of nerve entrapment lesion in chronic inflammatory demyelinating polyneuropathy. Clin Neurophysiol. 2004;115(5):1140-1144. doi:10.1016/j.clinph.2003.12.007. 62. Pascual-Goni E, Martin-Aguilar L, Lleixa C, et al. Clinical and laboratory features of anti-MAG neuropathy without monoclonal gammopathy. Sci Rep. 2019;9(1):6155. doi:10.1038/ s41598-019-42545-8. 63. Pegat A, Boisseau W, Maisonobe T, et al. Motor chronic inflammatory demyelinating polyneuropathy (CIDP) in 17 patients: clinical characteristics, electrophysiological study, and response to treatment. J Peripher Nerv Syst. 2020;25:162-170. 64. Press R, Pashenkov M, Jin JP, Link H. Aberrated levels of cerebrospinal fluid chemokines in Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J Clin Immunol. 2003;23(4):259-267. doi:10.1023/A:1024532715775. 65. Querol L, Nogales-Gadea G, Rojas-Garcia R, et al. Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology. 2014;82(10):879886. doi: 10.1212/WNL.0000000000000205. 66. Querol L, Siles AM, Alba-Rovira R, et al. Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy. Sci Rep. 2017;7(1). doi:10.1038/ s41598-017-14853-4. 67. Rajabally YA, Chavada G. Lewis-Sumner syndrome of pure upper-limb onset: diagnostic, prognostic, and therapeutic features. Muscle Nerve. 2009;39(2):206-220. doi:10.1002/mus.21199. 68. Rajabally YA, Narasimhan M. Electrophysiological entrapment syndromes in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2011;44(3):444-447. doi:10.1002/mus.22146. 69. Rajabally YA, Narasimhan M. Distribution, clinical correlates and significance of axonal loss and demyelination in chronic inflammatory demyelinating polyneuropathy. Eur J Neurol. 2011;18(2):293-299. doi:10.1111/j.1468-1331.2010.03138.x. 70. Rajabally YA, Afzal S. Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy. J Neurol. 2019;266:461-467. 71. Rajabally YA, Afzal S, Loo LK, Goedee HS. Application of the 2021 EAN/PNS criteria for chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatr. 2022;93(12):1247-1252. doi:10.1136/jnnp-2022-329633. 72. Ruts L, Drenthen J, Jacobs BC, van Doorn PA; Dutch GBS Study Group. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology. 2010 May 25;74(21):1680-6. doi: 10.1212/ WNL.0b013e3181e07d14. 73. Sakamoto Y, Shimizu T, Tobisawa S, Isozaki E. Chronic demyelinating neuropathy with anti-myelin-associated glycoprotein antibody without any detectable M-protein. Neurol Sci. 2017;38(12):2165-2169. doi:10.1007/s10072-017-3133-0. 74. Sommer C, Koch S, Lammens M, Gabreels-Festen A, Stoll G, Toyka KV. Macrophage clustering as a diagnostic marker in sural nerve biopsies of patients with CIDP. Neurology. 2005;65(12):1924-1929. doi:10.1212/01.wnl.0000188879.19900.b7. 75. Sugimoto T, Ochi K, Hosomi N, et al. Ultrasonographic nerve enlargement of the median and ulnar nerves and the cervical nerve roots in patients with demyelinating Charcot-Marie-Tooth disease: distinction from patients with chronic inflammatory demyelinating polyneuropathy. J Neurol. 2013;260(10):2580-2587. doi:10.1007/ s00415-013-7021-0. 76. Tanaka K, Mori N, Yokota Y, Suenaga T. MRI of the cervical nerve roots in the diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy: a single-institution, retrospective case-control study. BMJ Open. 2013;3(8):e003443. doi:10.1136/bmjopen-2013-003443. 77. Telleman JA, Herraets IJT, Goedee HS, et al. Nerve ultrasound: a reproducible diagnostic tool in peripheral neuropathy. Neurology. 2019;92(5). doi:10.1212/ WNL.0000000000006856. 78. Turčanová Koprušáková M, Šveda K, Grofik M, et al. Nodopatie a paranodopatie – nový pohľad na diagnostiku a terapiu imunitne podmienených polyneuropatií. Neurológia. 2023;18(2):101-107. 79. Uncini A, Kuwabara S. Nodopathies of the peripheral nerve: an emerging concept. J Neurol Neurosurg Psychiatr. 2015;86(11):1186-1195. doi:10.1136/jnnp-2014-310097. 80. Vallat JM, Tabaraud F, Magy L, et al. Diagnostic value of nerve biopsy for atypical chronic inflammatory demyelinating polyneuropathy: evaluation of eight cases. Muscle Nerve. 2003;27(4):478-485. doi:10.1002/mus.10348. 81. Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/peripheral nerve society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force-second revision. Eur J Neurol. 2021;28(11):35563583. doi:10.1111/ene.14959. 82. Van den Bergh PY, Hadden RD, Bouche P, et al. European federation of neurological societies/peripheral nerve society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European federation of neurological societies and the peripheral nerve society – first revision. Eur J Neurol. 2010;17(3):356-363. doi:10.1111/j.1468-1331.2009.02930.x. 83. van Doorn IN, Eftimov F, Wieske L, et al. Challenges in the Early Diagnosis and Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Adults: Current Perspectives. Ther Clin Risk Manag. 2024 Feb 14;20:111-126. doi: 10.2147/TCRM.S360249. 84. van Lieverloo GGA, Peric S, Doneddu PE, et al. Corticosteroids in chronic inflammatory demyelinating polyneuropathy: a retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone. J Neurol. 2018;265(9):2052-2059. doi:10.1007/s00415-018-8948-y. 85. van Rosmalen MHJ, Goedee HS, van der Gijp A, et al. Low interrater reliability of brachial plexus MRI in chronic inflammatory neuropathies. Muscle Nerve. 2020;61(6):779-783. doi:10.1002/mus.26821. 86. van Schaik IN, Bril V, van Geloven N, et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet Neurol. 2018;17(1):35-46. doi:10.1016/S1474-4422(17)30378-2. 87. van Schaik IN, Mielke O, Bril V, et al. Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study. Neurol Neuroimmunol Neuroinflamm. 2019;6:e590. 88. van Veen R, Wieske L, Lucke I, et al. Assessing deterioration using impairment and functional outcome measures in chronic inflammatory demyelinating polyneuropathy: a post-hoc analysis of the immunoglobulin overtreatment in CIDP trial. J Peripher Nerv Syst. 2022;27(2):144-158. doi:10.1111/jns.12497. 89. Vural A, Doppler K, Meinl E. Autoantibodies against the node of Ranvier in seropositive chronic inflammatory demyelinating polyneuropathy: diagnostic, pathogenic, and therapeutic relevance. Front Immunol. 2018;9:1029. doi:10.3389/fimmu.2018.01029. 90. Zaidman CM, Al-Lozi M, Pestronk A. Peripheral nerve size in normal and patients with polyneuropathy: an ultrasound study. Muscle Nerve. 2009;40(6):960-966. doi:10.1002/mus.21431.
RkJQdWJsaXNoZXIy NDA4Mjc=